Literature DB >> 26970938

[How to define treatment-resistant depression?].

Jérôme Holtzmann1, Raphaëlle Richieri2, Ghassen Saba3, Najib Allaïli4, Rémy Bation5, Fanny Moliere6, Isabel Nieto4, Frank Bellivier4, Djamila Bennabi7, Maxime Bubrovszky8, Vincent Camus9, Thomas Charpeaud10, Pierre Courvoisier11, Frédéric Haesebaert5, Olivier Doumy12, Philippe Courtet6, Wissam El-Hage9, Marion Garnier10, Thierry d'Amato5, Christophe Lançon2, Marion Leboyer3, Pierre-Michel Llorca10, Guillaume Vaiva8, Thierry Bougerol11, Bruno Aouizerate12, Emmanuel Haffen7.   

Abstract

The most largely used definition of the treatment-resistant depression relies on the failure of two successive trials of antidepressant treatment at an adequate dose and duration. The absence of response to previous antidepressant treatments should be assessed using specific and appropriate clinical instruments enabling a correct staging of the therapeutic resistance. A wide range of socio-demographic and clinical factors (i.e. psychiatric/somatic comorbidities) are classically associated with the therapeutic resistance. The aim of the treatment of major depression is to achieve a complete clinical remission. The presence of residual symptoms increases the risk for the subsequent occurrence of relapses and recurrences, hence facilitating the development of therapeutic resistance. The treatment-resistant depression has a deleterious impact on the social, familial or professional functioning, thereby leading to an impaired quality of life with serious socioeconomic consequences and costs.
Copyright © 2016. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26970938     DOI: 10.1016/j.lpm.2016.02.002

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  6 in total

Review 1.  Investigational drugs in recent clinical trials for treatment-resistant depression.

Authors:  Ricardo P Garay; Carlos A Zarate; Thomas Charpeaud; Leslie Citrome; Christoph U Correll; Ahcène Hameg; Pierre-Michel Llorca
Journal:  Expert Rev Neurother       Date:  2017-01-29       Impact factor: 4.618

2.  Cost-utility analysis of transcranial direct current stimulation (tDCS) in non-treatment-resistant depression: the DISCO randomised controlled study protocol.

Authors:  Anne Sauvaget; Lydie Lagalice; Solène Schirr-Bonnans; Christelle Volteau; Morgane Péré; Cécile Dert; Annabelle Rivalland; Fabienne Tessier; Adeline Lepage; Agathe Tostivint; Thibault Deschamps; Véronique Thomas-Ollivier; Alison Robin; Noémie Pineau; Clémence Cabelguen; Nicolas Bukowski; Marie Guitteny; Auxane Beslot; Luc Simons; Hugopsy Network; Jean-Marie Vanelle; Giordano D'Urso; Samuel Bulteau; Valéry-Pierre Riche
Journal:  BMJ Open       Date:  2020-01-13       Impact factor: 2.692

3.  Vagus Nerve Stimulation For Treatment Resistant Depression: Case Series Of Six Patients - Retrospective Efficacy And Safety Observation After One Year Follow Up.

Authors:  Krzysztof Kucia; Wojciech Merk; Krzysztof Zapalowicz; Tomasz Medrala
Journal:  Neuropsychiatr Dis Treat       Date:  2019-11-25       Impact factor: 2.570

4.  Treatment-Resistant Depression in a Real-World Setting: First Interim Analysis of Characteristics, Healthcare Resource Use, and Utility Values of the FondaMental Cohort.

Authors:  Antoine Yrondi; Djamila Bennabi; Emmanuel Haffen; Delphine Quelard; Ludovic Samalin; Julia Maruani; Etienne Allauze; Damien Pierre; Thierry Bougerol; Vincent Camus; Thierry D'Amato; Olivier Doumy; Jérôme Holtzmann; Christophe Lançon; Fanny Moliere; Rémi Moirand; Isabel Nieto; Raphaëlle Marie Richieri; Mathilde Horn; Laurent Schmitt; Florian Stephan; Jean-Baptiste Genty; Guillaume Vaiva; Michel Walter; Philippe Courtet; Marion Leboyer; Pierre-Michel Llorca; Sophie Marguet; Nathalie Dennis; Dominique Schaetz; Wissam El-Hage; Bruno Aouizerate
Journal:  Brain Sci       Date:  2020-12-10

5.  Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study.

Authors:  Maud Rothärmel; Cherifa Benosman; Wissam El-Hage; Caroline Berjamin; Diane Ribayrol; Olivier Guillin; Raphaël Gaillard; Lucie Berkovitch; Virginie Moulier
Journal:  Front Psychiatry       Date:  2022-07-08       Impact factor: 5.435

Review 6.  Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use.

Authors:  Helge H O Müller; Sebastian Moeller; Caroline Lücke; Alexandra P Lam; Niclas Braun; Alexandra Philipsen
Journal:  Front Neurosci       Date:  2018-04-10       Impact factor: 4.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.